Amarantus Bioscience Holdings Inc (AMBS)

[Chelby84]

NEWS OUT !!!

Account" tab.
News for 'AMBS' - (Amarantus BioScience President and CEO Publishes New Blog Entitled ''Continued Progress with our Business Plan in Central Nervous System Disorders'')


May 16, 2013 (ACCESSWIRE-TNW via COMTEX) -- Amarantus BioScience, Inc. (OTCQB:
AMBS) today published a blog post entitled "Continued Progress with our Business
Plan in Central Nervous System Disorders" on TheChairmansBlog.com.

Amarantus President and CEO, Gerald Commissiong, updates shareholders on an
"aggressive growth strategy for the Company's key products, MANF and LymPro."
Mr. Commissiong explains how the Company seeks to create multiple opportunities
and mitigate risk in both of its Therapeutics and Diagnostics divisions. Read
the full blog post from Gerald Commissiong on TheChairmansBlog.com
(http://www.thechairmansblog.com/gerald-commissiong/2013-05/continued-progress-with-our-business-plan-in-central-nervous-system-disorders.html).

About Amarantus BioScience, Inc.

AmarantusBioScience, Inc. is a development-stage biotechnology company founded
in January 2008. The Company has a focus on developing certain biologics
surrounding the intellectual property and proprietary technologies it owns to
treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other
human diseases. The Company owns the intellectual property rights to a
therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor
("MANF") and is developing MANF-based products as treatments for brain
disorders. The Company also is a Founding Member of the Coalition for Concussion
Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports
International seeking to raise awareness of new treatments in development for
concussions and nervous-system disorders. For further information, please visit
www.amarantus.com.

About TheChairmansBlog.com